TheProductLawyers.com reports on the results of several recently concluded studies, that seem to support Xarelto lawsuit plaintiff’s allegations linking the anticoagulant to several dangerous, unexpected bleeding episodes. A multitude of Xarelto lawsuit plaintiffs have alleged that the blood-thinning drug can cause serious and even fatal uncontrollable bleeding episodes, which makes these new findings even more important to the rapidly approaching Xarelto bellwether court proceedings.
Xarelto was approved by The U.S. Food and Drug Administration (FDA) in 2011 to treat patients with an increased risk of blood clots or stroke. The blood thinner was intended to be given to those recovering from hip or knee replacement surgeries, and to individuals with deep vein thrombosis or pulmonary embolism. It was also approved for the treatment of those who have the common heart condition, atrial fibrillation, in order to reduce the risk of strokes. Shortly after Xarelto was released to the market, patients began to link the drug to several severely dangerous potential side effects.
After hearing of these potentially life-threatening side effects of Xarelto, doctors Judy Hun and John Hwang decided to take matters into their own hands and conduct a study to investigate the effects of the anticoagulant on their own patients. Throughout their study, the 2 doctors noticed that multiple patients had developed “spontaneous vitreous hemorrhage,” which is a form of eye bleeding while taking Xarelto. After further investigation, Hun and Hwang concluded that risks of eye bleeds are increased for patients who had switched to a Xarelto regimen after previously using a more traditional blood thinner.
Another study has also linked the use of Xarelto with unexpected bleeding episodes. This study was conducted from October 1st of 2010 to March 31st of 2012 and evaluated a large number of people across the U.S. who used the anticoagulants: Xarelto, Pradaxa, or warfarin. After observing a sample of 46,000 patients, including 39,607 warfarin users, 4,907 Pradaxa users, and 1,649 Xarelto users, results concluded that there is “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”
Currently, lawsuits have been filed against Xarelto manufacturers, Bayer AG and Janssen Pharmaceuticals, in over 2,800 cases in federal court. Following MDL No. 2592 in Louisiana, an additional 550 cases were consolidated into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas. The Honorable Judge Eldon E. Fallon has been tasked with the oversight of MDL No. 2592 in the Eastern District of Louisiana.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-478-9711.
###
Contact TheProductLawyers.com:
Banville Law
888-478-9711
info@banvillelaw.com
165 West End Ave #1h, New York, NY 10023
